{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T19:57:18Z","timestamp":1775591838800,"version":"3.50.1"},"reference-count":23,"publisher":"BMJ","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arch Dis Child Fetal Neonatal Ed"],"published-print":{"date-parts":[[2009,5]]},"abstract":"<jats:sec>\n                  <jats:title>Objective:<\/jats:title>\n                  <jats:p>To determine whether b-type natriuretic peptide (BNP) concentrations can guide treatment of patent ductus arteriosus (PDA) to reduce the number of indomethacin doses without increasing morbidity.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Design:<\/jats:title>\n                  <jats:p>Prospective, randomised, controlled trial.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Setting:<\/jats:title>\n                  <jats:p>Single-centre referral neonatal intensive care unit.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Patients:<\/jats:title>\n                  <jats:p>Infants with echocardiographic diagnosis of PDA. Infants with congenital heart disease or renal insufficiency were excluded.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Interventions:<\/jats:title>\n                  <jats:p>BNP measurement and echocardiography were performed in all subjects before and after indomethacin treatment. The investigational group had BNP concentrations measured 12 and 24 h after the first dose (before the 2nd and 3rd doses of indomethacin). Indomethacin dosing was withheld in the BNP-guided group if the 12 or 24 h BNP concentrations were found to be &lt;100 pg\/ml.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Main outcome measures:<\/jats:title>\n                  <jats:p>Number of doses of indomethacin given during the primary course of treatment (three doses every 12 h).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results:<\/jats:title>\n                  <jats:p>Sixty patients were randomly assigned to control (n\u200a=\u200a30) and BNP-guided (n\u200a=\u200a30) treatment groups. There was no difference between the groups with respect to gestational age (26<jats:sup>+3<\/jats:sup> vs 25<jats:sup>+5<\/jats:sup> weeks, respectively), Apgar scores, delivery method, gender or indomethacin prophylaxis. Median baseline and 48 h BNP concentrations did not differ between the groups (0 h: 500 vs 542 pg\/ml; 48 h: 85 vs 126 pg\/ml; control and BNP-guided groups, respectively). During primary indomethacin treatment, the BNP-guided group received fewer doses of indomethacin than controls (70 vs 88 doses, p&lt;0.05). The rate of PDA ligation, intestinal perforation and chronic lung disease did not differ between groups.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions:<\/jats:title>\n                  <jats:p>BNP-guided treatment reduced the number of primary indomethacin doses. There was no increase in PDA persistence or associated morbidity.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/adc.2008.147587","type":"journal-article","created":{"date-parts":[[2008,11,3]],"date-time":"2008-11-03T20:30:09Z","timestamp":1225744209000},"page":"F178-F182","source":"Crossref","is-referenced-by-count":38,"title":["B-type natriuretic peptide concentrations to guide treatment of patent ductus arteriosus"],"prefix":"10.1136","volume":"94","author":[{"given":"J T","family":"Attridge","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D A","family":"Kaufman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D S","family":"Lim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2008,11,3]]},"reference":[{"key":"2025090513424920000_94.3.F178.1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197609022951004"},{"key":"2025090513424920000_94.3.F178.2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197609022951003"},{"key":"2025090513424920000_94.3.F178.3","doi-asserted-by":"publisher","DOI":"10.1038\/sj.jp.7211429"},{"key":"2025090513424920000_94.3.F178.4","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1542\/peds.67.5.647","article-title":"Indomethacin treatment for symptomatic patent ductus arteriosus: a double-blind control study.","volume":"67","author":"Yanagi","year":"1981","journal-title":"Pediatrics"},{"key":"2025090513424920000_94.3.F178.5","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3476(83)80022-5"},{"key":"2025090513424920000_94.3.F178.6","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2005-0293"},{"key":"2025090513424920000_94.3.F178.7","doi-asserted-by":"publisher","DOI":"10.1067\/mpd.2001.110528"},{"key":"2025090513424920000_94.3.F178.8","doi-asserted-by":"publisher","DOI":"10.1097\/00008480-200404000-00005"},{"key":"2025090513424920000_94.3.F178.9","doi-asserted-by":"publisher","DOI":"10.1097\/01.PCC.0000224998.97784.A3"},{"key":"2025090513424920000_94.3.F178.10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa020233"},{"key":"2025090513424920000_94.3.F178.11","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2004-1837"},{"key":"2025090513424920000_94.3.F178.12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2005.03.040"},{"key":"2025090513424920000_94.3.F178.13","doi-asserted-by":"publisher","DOI":"10.1038\/sj.jp.7211383"},{"key":"2025090513424920000_94.3.F178.14","doi-asserted-by":"publisher","DOI":"10.1016\/j.echo.2005.10.005"},{"key":"2025090513424920000_94.3.F178.15","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9149(83)90582-9"},{"key":"2025090513424920000_94.3.F178.16","doi-asserted-by":"publisher","DOI":"10.1038\/sj.jp.7211407"},{"key":"2025090513424920000_94.3.F178.17","doi-asserted-by":"publisher","DOI":"10.1002\/sim.1688"},{"key":"2025090513424920000_94.3.F178.18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2006.12.048"},{"key":"2025090513424920000_94.3.F178.19","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.164.18.1978"},{"key":"2025090513424920000_94.3.F178.20","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2004-0525"},{"key":"2025090513424920000_94.3.F178.21","doi-asserted-by":"publisher","DOI":"10.1213\/01.ane.0000263644.98314.e2"},{"key":"2025090513424920000_94.3.F178.22","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2006.11.039"},{"key":"2025090513424920000_94.3.F178.23","doi-asserted-by":"publisher","DOI":"10.1038\/sj.jp.7211662"}],"container-title":["Archives of Disease in Childhood - Fetal and Neonatal Edition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/adc.2008.147587","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,5]],"date-time":"2025-09-05T20:43:01Z","timestamp":1757104981000},"score":1,"resource":{"primary":{"URL":"https:\/\/fn.bmj.com\/lookup\/doi\/10.1136\/adc.2008.147587"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,11,3]]},"references-count":23,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2009,4,21]]},"published-print":{"date-parts":[[2009,5]]}},"alternative-id":["10.1136\/adc.2008.147587"],"URL":"https:\/\/doi.org\/10.1136\/adc.2008.147587","relation":{},"ISSN":["1359-2998","1468-2052"],"issn-type":[{"value":"1359-2998","type":"print"},{"value":"1468-2052","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,11,3]]}}}